• Home
  • EXAMON Handelsges.m.b.H.

EXAMON Handelsges.m.b.H.

About EXAMON Handelsges.m.b.H.

Examon is a service provider specializing in business development for emerging markets within the pharmaceutical industry. With over 30 years of expertise, the company delivers comprehensive, end-to-end supply chain solutions. Furthermore, Examon’s subsidiary, Noavaran Daroui Kimia, dedicates itself to the development and production of targeted medicinal products and high-quality active pharmaceut...

Read more Show less
Certifications
  • CE
    CE
  • GMP
    GMP
  • ISO
    ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Austria
  • On CPHI since:
    2024
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
API Producer
Generic APIs producer
Pharmaceutical Company (generic finished products)
Contact info
Show contact info Hide contact info

Products from EXAMON Handelsges.m.b.H. (3)

  • Erlotinib-KIMOTAR®

    Product Erlotinib-KIMOTAR®

    • Erlotinib blocks the epidermal growth factor receptor’s tyrosine kinase to suppress tumor cell growth. • Validated efficacy in non-small cell lung cancer (first-line). • Offered in tablet form to facilitate patient-friendly, outpatient treatment. • Underpinned by a wide range of peer-reviewed studies...
  • Imatinib

    Product Imatinib

    • Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line). • Clinically established with robust trials confirming its ability to control disease pro...
  • Gefitinib-GEFISA®

    Product Gefitinib-GEFISA®

    • Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth. •  An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation. • Robust clinical studies confirm benefits in non-small cell lung and pan...